XprESS ET Registry

Sponsor
Entellus Medical, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT04136977
Collaborator
North American Science Associates (NAMSA) (Other)
169
11
26.8
15.4
0.6

Study Details

Study Description

Brief Summary

A prospective, multicenter, registry of patients undergoing balloon dilation of the Eustachian tubes (ET).

Condition or Disease Intervention/Treatment Phase
  • Device: Eustachian tube dilation

Detailed Description

This is a prospective, multicenter, single-arm, postmarket registry enrolling up to 300 participants who are planning to undergo balloon dilation of the Eustachian tubes for treatment of chronic/persistent Eustachian tube dysfunction (ETD). Procedural information will be collect as well as efficacy and safety data through 6 months post procedure.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
169 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
XprESS Eustachian Tube Balloon Dilation Registry
Actual Study Start Date :
Jun 5, 2018
Actual Primary Completion Date :
Aug 28, 2020
Actual Study Completion Date :
Aug 28, 2020

Outcome Measures

Primary Outcome Measures

  1. Change in mean Eustachian Tube Dysfunction Questionnaire (ETDQ-7) score [6 Months]

    Change from baseline to follow-up in the mean overall ETDQ-7 score. The ETDQ-7 is a validated 7-item patient-reported questionnaire reporting the presence and severity of symptoms associated with Eustachian tube dysfunction. Each item is scored from 1 (normal) to 7 (severe). The overall score is the mean score of the 7 items.

  2. Complication rate [6 Months]

    Percentage of participants who experience 1 or more serious adverse events that are related to the device and/or procedure.

Secondary Outcome Measures

  1. Procedural information [Procedure through 6-week follow-up]

    Details of the balloon dilation procedure, including setting, anesthesia, technical success, concomitant procedures, procedure/device-related adverse events, and recovery time.

  2. Minimal clinically important difference in ETDQ-7 score [6 Months]

    Percentage of participants achieving the minimal clinical important difference in overall ETDQ-7 score (reduction from baseline of 0.5 points or more). The ETDQ-7 is a validated 7-item patient-reported questionnaire reporting the presence and severity of symptoms associated with Eustachian tube dysfunction. Each item is scored from 1 (normal) to 7 (severe). The overall score is the mean score of the 7 items.

  3. Revision Eustachian tube dilation [6 Months]

    Percentage of participants who require revision dilation on an ear that was treated in the initial procedure.

  4. Surgical interventions [6 Months]

    Percentage of participants requiring surgical ear intervention (other than balloon dilation) on an ear that was treated in the initial procedure but has recurrent or continuing ETD symptoms.

  5. Participant satisfaction: Proportion of participants indicating satisfaction and willing to recommend the procedure to friends or family [6 Months]

    Percentage of participants indicating satisfaction and willing to recommend the procedure to friends or family.

  6. Change in work productivity/activity impairment [6 Months]

    Participants complete the validated Work Productivity and Activity Impairment (WPAI) at baseline and 6 month follow-up. The questionnaire consists of 6 questions that evaluate absenteeism, presenteeism, work productivity loss, and activity impairment over the previous week. Results are expressed as the percentage of impairment from 0 to 100, for which higher numbers indicate worse outcomes (ie, greater impairment and less productivity). Absenteeism is calculated by dividing the number of hours missed by the sum of the numbers of hours missed plus the number of hours worked. Presenteeism, is calculated by dividing the response to productivity at work question by 10, while activity impairment is calculated by dividing the response to the ability to carry out daily activities question by 10. Finally, the overall work impairment/productivity loss is calculated as the sum of absenteeism and the product of presenteeism and time at work.

  7. Change from baseline in chronic rhinosinusitis symptoms [6 Months]

    Participants will complete the validated 22-item SinoNasal Outcomes Test (SNOT-22) to evaluate change in chronic rhinosinusitis symptoms. Each of the 22 symptoms on the questionnaire are rated by the participant from 0 (no problem) to 5 (bad). A sum of the 22 item scores provides the overall score, which can range from 0 to 110.

  8. Improvement in tympanogram [6 Months]

    Percentage of participants with an abnormal tympanogram (type B or C) at baseline who have a normal (type A) or improved (type B to type C) tympanogram at follow-up.

  9. Improvement in ability to perform a Valsalva maneuver [6 Months]

    Percentage of participants unable to perform the Valsalva maneuver (negative) at baseline who are able to perform the maneuver (positive) at follow-up.

  10. Improvement in tympanic membrane position [6 Months]

    Percentage of participants with a retracted tympanic membrane at baseline who have a normal tympanic membrane position at follow-up.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Be at least 18 years old

  • Have been diagnosed with persistent/chronic Eustachian tube dysfunction (duration 3 months or more)

  • Be a candidate for unilateral or bilateral Eustachian tube balloon dilation using the XprESS device

  • Be able to read and understand English

  • Be willing and able to provide informed consent

  • Be willing to comply with the protocol requirements

Exclusion Criteria:
  • Have a history of patulous Eustachian tube

  • Require additional ear surgery (eg, myringotomy, tympanostomy) at the time of study procedure

  • Have evidence of internal carotid artery dehiscence

  • Be currently participating in any other drug or device clinical studies, excluding postapproval or marketing registry studies

Contacts and Locations

Locations

Site City State Country Postal Code
1 Breathe Clear Institute Torrance California United States 90503
2 Colorado ENT and Allergy Colorado Springs Colorado United States 80909
3 Augusta ENT and Allergy Evans Georgia United States 30809
4 St. Vincent Anderson Hospital Anderson Indiana United States 46016
5 Ochsner Clinic Foundation New Orleans Louisiana United States 70121
6 Ear Nose and Throat Consultants Southfield Michigan United States 48934
7 St Cloud ENT Saint Cloud Minnesota United States 56303
8 ENT Consultants of Nevada Las Vegas Nevada United States 89128
9 Lakeside ENT Canandaigua New York United States 14424
10 National Allergy and ENT Charleston South Carolina United States 29420
11 Medical University of South Carolina Charleston South Carolina United States 29425

Sponsors and Collaborators

  • Entellus Medical, Inc.
  • North American Science Associates (NAMSA)

Investigators

  • Principal Investigator: Edward D McCoul, MD, PhD, Ochsner Health System, New Orleans, LA

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Entellus Medical, Inc.
ClinicalTrials.gov Identifier:
NCT04136977
Other Study ID Numbers:
  • 4079-001
First Posted:
Oct 23, 2019
Last Update Posted:
Sep 30, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes

Study Results

No Results Posted as of Sep 30, 2020